Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?
· fool.com · popularity 21/100 · 0 similar stories today · Entrepreneurship & Startups (Business & Finance)
Read the original at fool.com →
Summary
The bladder-cancer drugmaker's sales jumped 53%, and a key trial hit its goal, yet the stock tumbled. The numbers behind the drop tell investors what …
Found in: The Motley Fool. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 1.